MAIA Biotechnology, Inc. (NYSE: MAIA) is set to present at the prestigious Biotech Showcase™ 2025, an all-inclusive life science conference taking place in San Francisco, CA, from January 13-15, 2025, followed by a virtual event on January 21-22, 2025. This invitation-only event brings together global biopharma leaders, investors, and industry experts to discuss the latest innovations and trends in the biotechnology sector. MAIA's participation in this event is a testament to its growing influence and potential in the biotech space.

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead product candidate, THIO, is a first-in-class investigational telomere-targeting agent currently in clinical development for the treatment of non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death, ultimately activating both innate and adaptive immune responses.

MAIA's CEO, Vlad Vitoc, M.D., will present at the conference on January 13, 2025, at 3:00 PM PST. During his presentation, Dr. Vitoc will discuss key developments, including the expansion of the THIO-101 pivotal Phase 2 clinical trial for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy. This trial is designed to evaluate the anti-tumor activity of THIO when followed by PD-(L)1 inhibition, with the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients.

Dr. Vitoc will also outline MAIA's plans for multiple THIO trials across additional cancer indications, building upon the promising preclinical results and orphan drug designations (ODDs) that THIO has already received for hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and glioblastoma. These trials will further explore THIO's potential in various cancer types, addressing significant unmet needs and market opportunities.

MAIA's partnership with global oncology company BeiGene to assess the efficacy of THIO in combination with tislelizumab, BeiGene's immune checkpoint inhibitor, in three cancer indications (HCC, SCLC, and colorectal cancer) is another significant development that Dr. Vitoc will highlight. This collaboration enables MAIA to evaluate THIO's potential in combination with a CPI in these indications, building upon the promising preclinical results that have already been observed.

MAIA's participation in Biotech Showcase 2025 provides an excellent opportunity for the company to showcase its innovative drug candidates, engage with potential partners and investors, and increase its visibility in the market. The conference's focus on innovation, collaboration, and market trends aligns perfectly with MAIA's strategic goals and market positioning.



In conclusion, MAIA Biotechnology's participation in Biotech Showcase 2025 is a significant milestone for the company, demonstrating its growing influence and potential in the biotech space. The conference provides an ideal platform for MAIA to showcase its innovative drug candidates, engage with potential partners and investors, and increase its visibility in the market. With its promising pipeline and strategic partnerships, MAIA is well-positioned to make a significant impact on the biotechnology industry.